Karen T Liby

List of Publications by Year in Descending Order

92 papers	6,797 citations	41 h-index	82 g-index
94 ext. papers	7,381 ext. citations	6.3 avg, IF	5.79 L-index

#	Paper	IF	Citations
92	T Cells and CDDO-Me Attenuate Immunosuppressive Activation of Human Melanoma-Conditioned Macrophages.. *Frontiers in Immunology*, **2022**, 13, 768753	8.4	0
91	The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer. *Cancers*, **2021**, 13,	6.6	3
90	Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting. *Journal of Cancer Prevention*, **2021**, 26, 71-82	3	0
89	A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy. *Molecular Cancer Therapeutics*, **2021**, 20, 1692-1701	6.1	1
88	Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice. *Scientific Reports*, **2021**, 11, 1234	4.9	1
87	Potential therapeutic uses of rexinoids. *Advances in Pharmacology*, **2021**, 91, 141-183	5.7	4
86	The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer. *Cancers*, **2020**, 13,	6.6	4
85	The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer. *Scientific Reports*, **2020**, 10, 22244	4.9	5
84	CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer. *Scientific Reports*, **2020**, 10, 6560	4.9	11
83	The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in Kras; Pdx1-Cre (KC) mice. *Scientific Reports*, **2019**, 9, 7072	4.9	10
82	Testing Novel Pyrimidinyl Rexinoids: A New Paradigm for Evaluating Rexinoids for Cancer Prevention. *Cancer Prevention Research*, **2019**, 12, 211-224	3.2	8
81	Identifying chemopreventive agents for obesity-associated cancers using an efficient, 3D high-throughput transformation assay. *Scientific Reports*, **2019**, 9, 10278	4.9	2
80	Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models. *Npj Breast Cancer*, **2019**, 5, 39	7.8	7
79	A BET Bromodomain Inhibitor Suppresses Adiposity-Associated Malignant Transformation. *Cancer Prevention Research*, **2018**, 11, 129-142	3.2	2
78	Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762. *Cancer Prevention Research*, **2018**, 11, 143-156	3.2	16
77	Identification of an Unfavorable Immune Signature in Advanced Lung Tumors from Nrf2-Deficient Mice. *Antioxidants and Redox Signaling*, **2018**, 29, 1535-1552	8.4	20
76	Nanoformulated Talazoparib enhances the efficacy and reduces the toxicity of this PARP inhibitor in a preclinical model of BRCA-deficient breast cancer. *FASEB Journal*, **2018**, 32, 565.10	0.9	1

75	Differential effects of the Nrf2 activators tBHQ and CDDO-Im on the early events of T cell activation. *Biochemical Pharmacology*, **2018**, 147, 67-76	6	20
74	Dehydroabietic oximes halt pancreatic cancer cell growth in the G1 phase through induction of p27 and downregulation of cyclin D1. *Scientific Reports*, **2018**, 8, 15923	4.9	8
73	Murine Models of Pancreatitis Leading to the Development of Pancreatic Cancer. *Current Protocols in Pharmacology*, **2018**, 83, e48	4.1	4
72	Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. *Cancer Letters*, **2017**, 394, 76-87	9.9	73
71	Nrf2-Dependent and -Independent Effects of -Butylhydroquinone, CDDO-Im, and HO in Human Jurkat T Cells as Determined by CRISPR/Cas9 Gene Editing. *Journal of Pharmacology and Experimental Therapeutics*, **2017**, 361, 259-267	4.7	12
70	Synthetic oleanane triterpenoids enhance blood brain barrier integrity and improve survival in experimental cerebral malaria. *Malaria Journal*, **2017**, 16, 463	3.6	10
69	Design, synthesis, and biological activity of second-generation synthetic oleanane triterpenoids. *Organic and Biomolecular Chemistry*, **2017**, 15, 6001-6005	3.9	8
68	Rexinoids for Prevention and Treatment of Cancer: Opportunities and Challenges. *Current Topics in Medicinal Chemistry*, **2017**, 17, 721-730	3	9
67	The Rexinoids LG100268 and LG101506 Inhibit Inflammation and Suppress Lung Carcinogenesis in A/J Mice. *Cancer Prevention Research*, **2016**, 9, 105-14	3.2	15
66	CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages. *PLoS ONE*, **2016**, 11, e0149600	3.7	25
65	The triterpenoid CDDO-imidazolide reduces immune cell infiltration and cytokine secretion in the KrasG12D;Pdx1-Cre (KC) mouse model of pancreatic cancer. *Carcinogenesis*, **2016**, 37, 1170-1179	4.6	9
64	Rexinoids for prevention and treatment of cancer: opportunities and challenges. *Current Topics in Medicinal Chemistry*, **2016**,	3	3
63	Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. *Pharmacological Research*, **2015**, 100, 135-47	10.2	19
62	Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis. *Carcinogenesis*, **2015**, 36, 769-81	4.6	46
61	Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. *Cell Cycle*, **2015**, 14, 648-55	4.7	49
60	Synthesis and biological evaluation of amino acid methyl ester conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid against the production of nitric oxide (NO). *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 532-4	2.9	10
59	The synthetic triterpenoid (CDDO-Im) inhibits STAT3, as well as IL-17, and improves DSS-induced colitis in mice. *Inflammopharmacology*, **2014**, 22, 341-9	5.1	23
58	An efficient synthesis of methyl 2-cyano-3,12-dioxoursol-1,9-dien-28-oate (CDDU-methyl ester): analogues, biological activities, and comparison with oleanolic acid derivatives. *Organic and Biomolecular Chemistry*, **2014**, 12, 5192-200	3.9	12

57	The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. *Cancer Prevention Research*, **2014**, 7, 698-707	3.2	55
56	PARP inhibitors for chemoprevention--reply. *Cancer Prevention Research*, **2014**, 7, 1172	3.2	0
55	Synthetic triterpenoids can protect against toxicity without reducing the efficacy of treatment with Carboplatin and Paclitaxel in experimental lung cancer. *Dose-Response*, **2014**, 12, 136-51	2.3	9
54	A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer. *PLoS ONE*, **2014**, 9, e107616	3.7	22
53	Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. *Antioxidants and Redox Signaling*, **2013**, 18, 139-57	8.4	125
52	Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression. *Cancer Prevention Research*, **2013**, 6, 959-70	3.2	18
51	Np63-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. *Cancer Research*, **2013**, 73, 1020-30	10.1	48
50	The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. *Carcinogenesis*, **2013**, 34, 199-210	4.6	35
49	Is lycopene an effective agent for preventing prostate cancer?. *Cancer Prevention Research*, **2013**, 6, 384-6	3.2	13
48	Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. *Pharmacological Reviews*, **2012**, 64, 972-1003	22.5	288
47	NRF2 and cancer: the good, the bad and the importance of context. *Nature Reviews Cancer*, **2012**, 12, 564-71	31.3	725
46	The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice. *Cancer Prevention Research*, **2012**, 5, 726-34	3.2	37
45	CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice. *Cancer Prevention Research*, **2012**, 5, 89-97	3.2	41
44	New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. *Journal of Natural Products*, **2011**, 74, 537-45	4.9	246
43	Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR. *PLoS ONE*, **2011**, 6, e22862	3.7	74
42	Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. *Free Radical Biology and Medicine*, **2011**, 51, 88-96	7.8	156
41	The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis. *Clinical and Experimental Metastasis*, **2011**, 28, 309-17	4.7	23
40	Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis. *Scientific Reports*, **2011**, 1, 201	4.9	71

39	CDDO-imidazolide induces DNA damage, G2/M arrest and apoptosis in BRCA1-mutated breast cancer cells. *Cancer Prevention Research*, **2011**, 4, 425-34	3.2	31
38	Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. *Cancer Prevention Research*, **2010**, 3, 1427-34	3.2	72
37	Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. *Clinical Cancer Research*, **2010**, 16, 1812-23	12.9	225
36	Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington disease. *Free Radical Biology and Medicine*, **2010**, 49, 147-58	7.8	134
35	2-Cyano-3,10-dioxooleana-1,9(11)-dien-28-oic acid anhydride. A novel and highly potent anti-inflammatory and cytoprotective agent. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 2275-8	2.9	9
34	Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. *PLoS ONE*, **2009**, 4, e5757	3.7	128
33	Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice. *Cancer Prevention Research*, **2009**, 2, 1050-8	3.2	42
32	Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 250-5	11.5	286
31	Synthetic triterpenoids attenuate cytotoxic retinal injury: cross-talk between Nrf2 and PI3K/AKT signaling through inhibition of the lipid phosphatase PTEN **2009**, 50, 5339-47		74
30	Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. *Carcinogenesis*, **2009**, 30, 1024-31	4.6	221
29	Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer disease. *Journal of Neurochemistry*, **2009**, 109, 502-12	6	91
28	A dicyanotriterpenoid induces cytoprotective enzymes and reduces multiplicity of skin tumors in UV-irradiated mice. *Biochemical and Biophysical Research Communications*, **2008**, 367, 859-65	3.4	13
27	Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268. *Clinical Cancer Research*, **2008**, 14, 4556-63	12.9	62
26	Human neuroblastoma cells rapidly enter cell cycle arrest and apoptosis following exposure to C-28 derivatives of the synthetic triterpenoid CDDO. *Cancer Biology and Therapy*, **2008**, 7, 709-17	4.6	21
25	The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. *Molecular Cancer Therapeutics*, **2008**, 7, 1251-7	6.1	30
24	Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice. *Toxicological Sciences*, **2008**, 104, 218-27	4.4	129
23	A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin. *Cancer Research*, **2008**, 68, 6727-33	10.1	44
22	Platforms and networks in triterpenoid pharmacology. *Drug Development Research*, **2007**, 68, 174-182	5.1	35

21	Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. *Nature Reviews Cancer*, **2007**, 7, 357-69	31.3	508
20	Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities. *Molecular Cancer Therapeutics*, **2007**, 6, 2113-9	6.1	53
19	A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland. *Clinical Cancer Research*, **2007**, 13, 6237-43	12.9	29
18	JunB and JunD regulate human heme oxygenase-1 gene expression in renal epithelial cells. *Journal of Biological Chemistry*, **2007**, 282, 6875-86	5.4	42
17	Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. *Antioxidants and Redox Signaling*, **2007**, 9, 1963-70	8.4	115
16	The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. *Cancer Research*, **2007**, 67, 2414-9	10.1	128
15	The synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by activating the Smad and ERK signaling pathways in HL60 leukemia cells. *Molecular Cancer Therapeutics*, **2006**, 5, 1452-8	6.1	40
14	The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. *Molecular Cancer Therapeutics*, **2006**, 5, 3232-9	6.1	105
13	Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. *Cancer Research*, **2006**, 66, 2488-94	10.1	171
12	The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. *Clinical Cancer Research*, **2006**, 12, 4288-93	12.9	101
11	The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. *Clinical Cancer Research*, **2006**, 12, 5902-9	12.9	48
10	Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide. *Biochemical and Biophysical Research Communications*, **2006**, 351, 883-9	3.4	272
9	Protection against UV-light-induced skin carcinogenesis in SKH-1 high-risk mice by sulforaphane-containing broccoli sprout extracts. *Cancer Letters*, **2006**, 240, 243-52	9.9	183
8	Cancer chemoprevention: scientific promise, clinical uncertainty. *Nature Clinical Practice Oncology*, **2005**, 2, 518-25		112
7	Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 4584-9	11.5	445
6	The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer. *Cancer Research*, **2004**, 64, 3566-71	10.1	57
5	Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid for the isolation of the protein targets. *Journal of Medicinal Chemistry*, **2004**, 47, 4923-32	8.3	51
4	Endostatin expression by MDA-MB-435 breast cancer cells effectively inhibits tumor growth. *Cancer Biology and Therapy*, **2003**, 2, 48-52	4.6	13

3	Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth. *Breast Cancer Research and Treatment*, **2003**, 79, 241-52	4.4	63
2	Prolactin as an autocrine/paracrine growth factor in human cancer. *Trends in Endocrinology and Metabolism*, **2002**, 13, 245-50	8.8	121
1	Proteolysis of human prolactin: resistance to cathepsin D and formation of a nonangiostatic, C-terminal 16K fragment by thrombin. *Endocrinology*, **1999**, 140, 4127-32	4.8	31